How many people are talking about Sarepta Therapeutics on Facebook?

931 people are talking about Sarepta Therapeutics on Facebook in the last 7 days. This is an increase compared to the 30 day moving average.

Analyzing Facebook Engagement, how is Sarepta Therapeutics performing compared to its industry peers?

Sarepta Therapeutics overperforms a majority of its industry peers when it comes to Facebook Engagement, ranking in the 92nd percentile.

Sarepta Therapeutics (SRPT) Facebook Engagement Statistics 2025

Company	Facebook Engagement
	Amgen AMGN	137 0%
	Gilead Sciences GILD	58 7.4%
	Catalyst Pharmaceuticals CPRX	6 20%
	Inovio Pharmaceuticals INO	1 0%
	Anavex Life Sciences AVXL	0 0%

Company

Facebook Engagement

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.